KTTA

Pasithea Therapeutics Corp. Common Stock (KTTA)

Stock · NASDAQ · Health Care

$0.425as of 10/16/2026

Price chart

Open in TradingView

Active signals

Volume Spike20.0%200 SMA Touch0.0%
Resistance level
$0.490625
Industry
Biotechnology: Pharmaceutical Preparations

KTTA Signal Track Record

How signals performed across all stocks →

What KTTA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume SpikeActive now27-7.3%30%
Bollinger Band Breakout22-5.5%36%
Bollinger Band Breakdown19-10.1%32%
200-Day Moving Average TouchActive now7-9.9%0%
Any 20-session window (baseline)-7.0%34%

Computed by MarketWall from daily closing prices since June 30, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About KTTA

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
5

Fundamentals

1-day range
$0.4001$0.43
Market cap
$14.82M
P/E (trailing)
—
P/E (forward)
-0.91
EPS (trailing)
$-1.48
Dividend yield
—
Beta
0.39
Avg. volume
216.3K
52-week range
$0.281$2.06

How Pasithea Therapeutics Corp. Common Stock Makes Money

Where the revenue actually goes — FY2022 annual results

market-wall.comTotalRevenue$486.6KSG&A$12.52M (2574%)Cost of Revenue$113.2K (23%)KTTA

Source: 10-K filed Mar 30, 2023 · via SEC EDGAR / Finnhub

Gross Profit$373.4K(77%)
Operating Income-$14.82M(-3045%)

Forecasts

1 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$3
+605.9%
Median
$3
+605.9%
Low
$3
+605.9%

Pasithea Therapeutics Corp. Common Stock Competitors

Chosen by industry and closest market cap.

  • KTTA
    Pasithea Therapeutics Corp. Common Stock
    $0.42
    ▲ 2.44%
    Market cap $14.82MP/E —
    $0.281$2.06
  • HIND
    Vyome Holdings Inc. Common Stock
    $1.87
    ▼ 2.09%
    Market cap $15.02MP/E —
    $1.75$6.56
  • SCNX
    Scienture Holdings Inc. Common Stock
    $3.36
    ▼ 0.59%
    Market cap $15.14MP/E —
    $3.21$65
  • TPST
    Tempest Therapeutics Inc. Common Stock
    $0.624
    ▼ 1.73%
    Market cap $14.42MP/E —
    $0.6801$12.23
  • KALA
    KALA BIO Inc. Common Stock
    $0.19
    ▼ 1.04%
    Market cap $14.25MP/E —
    $0.2593$95.5
  • COCP
    Cocrystal Pharma Inc. Common Stock
    $1.02
    ▼ 0.97%
    Market cap $14.20MP/E —
    $0.76$2.03
  • AKTX
    Akari Therapeutics plc ADS
    $8.18
    ▼ 7.47%
    Market cap $14.14MP/E Infinity
    $3.02$39.64

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
4.73M
Disposed
0

Institutional Ownership

March 31, 2026

Total shares held
12.77M
Total value held
$9.48M
Institutional holders
19
Top holders this quarter
  • Unknown2.10M
  • Unknown2.10M
  • Unknown2.10M
  • Unknown2.10M
  • Unknown1.35M
  • Unknown1.21M
  • Unknown831.3K
  • Unknown337.5K
  • Unknown290.6K
  • Unknown104.0K

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.